JP2020501531A5 - - Google Patents

Info

Publication number

JP2020501531A5

JP2020501531A5 JP2019527232A JP2019527232A JP2020501531A5 JP 2020501531 A5 JP2020501531 A5 JP 2020501531A5 JP 2019527232 A JP2019527232 A JP 2019527232A JP 2019527232 A JP2019527232 A JP 2019527232A JP 2020501531 A5 JP2020501531 A5 JP 2020501531A5

Authority

JP

Japan

Prior art keywords

antibody

antigen

binding fragment

seq

amino acid

Prior art date

2017-11-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims 34
• 239000000427 antigen Substances 0.000 claims 31
• 102000036639 antigens Human genes 0.000 claims 31
• 108091007433 antigens Proteins 0.000 claims 31
• 125000003275 alpha amino acid group Chemical group 0.000 claims 20
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 13
• 230000035772 mutation Effects 0.000 claims 13
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
• 150000001413 amino acids Chemical class 0.000 claims 7
• 210000004027 cell Anatomy 0.000 claims 6
• 206010028980 Neoplasm Diseases 0.000 claims 5
• 108020004707 nucleic acids Proteins 0.000 claims 5
• 102000039446 nucleic acids Human genes 0.000 claims 5
• 150000007523 nucleic acids Chemical class 0.000 claims 5
• 108091035707 Consensus sequence Proteins 0.000 claims 4
• 239000003814 drug Substances 0.000 claims 4
• 239000002773 nucleotide Substances 0.000 claims 4
• 125000003729 nucleotide group Chemical group 0.000 claims 4
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
• 201000011510 cancer Diseases 0.000 claims 3
• 231100000433 cytotoxic Toxicity 0.000 claims 3
• 230000001472 cytotoxic effect Effects 0.000 claims 3
• 102000050327 human TNFRSF9 Human genes 0.000 claims 3
• 229940124597 therapeutic agent Drugs 0.000 claims 3
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
• 102000009109 Fc receptors Human genes 0.000 claims 2
• 108010087819 Fc receptors Proteins 0.000 claims 2
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
• 210000001744 T-lymphocyte Anatomy 0.000 claims 2
• 238000002648 combination therapy Methods 0.000 claims 2
• 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 2
• 230000001419 dependent effect Effects 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 239000013598 vector Substances 0.000 claims 2
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
• 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
• 206010005003 Bladder cancer Diseases 0.000 claims 1
• 206010005949 Bone cancer Diseases 0.000 claims 1
• 208000018084 Bone neoplasm Diseases 0.000 claims 1
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 229940116741 CD137 agonist Drugs 0.000 claims 1
• 206010008342 Cervix carcinoma Diseases 0.000 claims 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
• 102000018297 Immunoglobulin subtype Human genes 0.000 claims 1
• 108050007411 Immunoglobulin subtype Proteins 0.000 claims 1
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
• 241000282567 Macaca fascicularis Species 0.000 claims 1
• 208000034578 Multiple myelomas Diseases 0.000 claims 1
• 201000004458 Myoma Diseases 0.000 claims 1
• 206010029260 Neuroblastoma Diseases 0.000 claims 1
• 206010033128 Ovarian cancer Diseases 0.000 claims 1
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
• 206010060862 Prostate cancer Diseases 0.000 claims 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
• 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
• 206010038389 Renal cancer Diseases 0.000 claims 1
• 208000000453 Skin Neoplasms Diseases 0.000 claims 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 1
• 230000001580 bacterial effect Effects 0.000 claims 1
• 201000010881 cervical cancer Diseases 0.000 claims 1
• 230000000112 colonic effect Effects 0.000 claims 1
• 238000004132 cross linking Methods 0.000 claims 1
• 230000009260 cross reactivity Effects 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 239000002254 cytotoxic agent Substances 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 239000013604 expression vector Substances 0.000 claims 1
• 208000005017 glioblastoma Diseases 0.000 claims 1
• 210000005260 human cell Anatomy 0.000 claims 1
• 229910052739 hydrogen Inorganic materials 0.000 claims 1
• 210000002865 immune cell Anatomy 0.000 claims 1
• 230000036039 immunity Effects 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 201000010982 kidney cancer Diseases 0.000 claims 1
• 208000032839 leukemia Diseases 0.000 claims 1
• 201000005202 lung cancer Diseases 0.000 claims 1
• 208000020816 lung neoplasm Diseases 0.000 claims 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
• 210000004962 mammalian cell Anatomy 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000007246 mechanism Effects 0.000 claims 1
• 201000001441 melanoma Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 201000002528 pancreatic cancer Diseases 0.000 claims 1
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 229920001184 polypeptide Polymers 0.000 claims 1
• 102000004196 processed proteins & peptides Human genes 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 claims 1
• 206010038038 rectal cancer Diseases 0.000 claims 1
• 201000001275 rectum cancer Diseases 0.000 claims 1
• 201000000849 skin cancer Diseases 0.000 claims 1
• 230000000699 topical effect Effects 0.000 claims 1
• 201000005112 urinary bladder cancer Diseases 0.000 claims 1